New ways to manipulate iPSC-derived neurons help reveal new disease phenotypes of Parkinson's disease (PD) and identify new clinical interventions. Creative Bioarray has worked to establish PD-specific iPSC models by reprogramming somatic cells from PD patients to help clients enhance their understanding of cellular progression of neurodegeneration in vitro.
iPSC for PD Modeling
PD is a common neurodegenerative disease of the elderly, characterized by progressive loss of dopaminergic neurons in the substantia nigra. The disease is associated with a variety of motor symptoms such as bradykinesia, postural instability and resting tremor, as well as a wide range of non-motor symptoms such as cognitive decline, sleep disturbances and olfactory disturbances, severely reducing the quality of life of patients. However, our incomplete understanding of the pathophysiology and etiology of neurodegenerative diseases has limited the development of therapeutic strategies for PD.
Robust preclinical screening tools for drug validation are a key element needed for successful drug development. Several culture systems have been developed to investigate the pathogenesis of PD or to determine promising drug leads. Currently, the establishment of PD-specific iPSC models addresses the shortcomings of traditional in vitro cell culture techniques that do not replicate the organization of cells and extracellular matrix (ECM) within the CNS. Through the propagation and differentiation of patient-derived iPSC into specific neuronal subtypes, researchers have established reproducible models more closely related to human pathophysiology to enhance understanding of PD disease mechanisms.
Fig.1 Parkinson's Disease model. (Valadez-Barba, 2020)
Our Solutions
Researchers at Creative Bioarray provide expert technical support and solutions to our clients, and we have developed several strategies for creating complex 3D models of midbrain tissue from iPSCs to help clients explore the pathogenesis of PD.
- Establishment of idiopathic PD organoid models. We differentiate iPSC derived from idiopathic PD patients into large multicellular organoid-like structures and then help our clients explore PD pathogenesis by observing differences in early and late neuronal marker expression when comparing healthy individuals and organoids prepared from PD patients.
- Establishment of human iPSC-derived PD neuronal models. We use iPSC from patients to generate more accurate disease models and to help clients investigate the significance of mitochondrial dysfunction, lysosomal degradation pathways and impaired mitochondrial autophagy in its pathogenesis.
Applications
- Research on pathogenic mechanisms of neurological disorders
- Study on early pathogenic mechanisms
- Development of personalized therapeutic strategies
Advantages
- Advanced technology and professional solutions
- High-quality technical support
- Customer-focused services
Equipped with an advanced cell reprogramming platform and professional cell culture technology, Creative Bioarray is capable of providing iPSC-based PD modeling services to our customers. Our innovative technologies provide valuable and unique tools for our clients to elucidate the pathogenesis of PD. Please contact us directly if you need scientific help.
Reference
- Valadez-Barba, V.; et al. iPSC for modeling neurodegenerative disorders. Regenerative Therapy. 2020, 15: 332-339.